N-Isopropyl-N'-tert.-butylpropan-1,3-diamin | 28286-20-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-Isopropyl-N'-tert.-butylpropan-1,3-diamin
• 英文别名: N'-tert-butyl-N-propan-2-ylpropane-1,3-diamine
• CAS: 28286-20-6
• 化学式: C₁₀H₂₄N₂
• mdl: MFCD12783680
• 分子量: 172.314
• InChiKey: BWEOWXJEKLPWJI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  异丙胺 、 叔丁胺 、 丙烯醛 生成 N-Isopropyl-N'-tert.-butylpropan-1,3-diamin
  参考文献：
  名称：

  饱和杂环的构象分析。第二十三部分。六氢嘧啶

  摘要：

  描述了一些N-取代的六氢嘧啶的制备。它们的电偶极矩已在环己烷溶液中测量，并根据其构象进行了解释。轴向和赤道的N-甲基和N-乙基之间的构象自由能差略小于相应的N-烷基哌啶，并且与两个轴向孤电子对之间的排斥力约为0·3 kcal./mol。对于N-异丙基，其构象自由能差高得惊人。建议一个可能的解释。

  DOI：

  10.1039/j29700000131

文献信息

• Compositions and methods for treating cancer
  申请人：The Regents of the University of California

  公开号：US10023588B2

  公开（公告）日：2018-07-17

  K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.

  K-Ras 是人类癌症中最常见的突变癌基因。本文公开了调节 K-Ras 和治疗癌症的组合物和方法。
• DISPERSED COMPOSITION, POLYMERIZABLE COMPOSITION, LIGHT SHIELDING COLOR FILTER, LIQUID CRYSTAL DISPLAY DEVICE HAVING LIGHT SHIELDING COLOR FILTER, SOLID-STATE IMAGING DEVICE, WAFER-LEVEL LENS, AND IMAGING UNIT HAVING WAFER LEVEL LENS
  申请人：Nagata Yuzo

  公开号：US20110279759A1

  公开（公告）日：2011-11-17

  The invention provides a dispersed composition including: (A) titanium black; (B) a polymer compound including a constituent component having a side chain structure to which an acidic group is linked via a linking group; and (C) a solvent. The (B) polymer compound is a polymer having a structure in which an acidic group is linked to a main chain part via a linking group.
• 8-AZA Tetracycline Compounds
  申请人：Clark Roger B.

  公开号：US20120108569A1

  公开（公告）日：2012-05-03

  The present invention is directed to a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.
• COMPOSITIONS AND METHODS FOR TREATING CANCER
  申请人：The Regents of the University of California

  公开号：US20200255446A1

  公开（公告）日：2020-08-13

  K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.
• US8367654B2
  申请人：——

  公开号：US8367654B2

  公开（公告）日：2013-02-05